Astrazeneca Share News (AZN)

UPDATE 2-Galenica to buy biotech firm Relypsa for $1.5 bln, ahead of split

* Deal brings worldwide rights to potassium medicine * Builds up Vifor Pharma unit ahead of 2017 split * Galenica shares down 7 percent (Adds analyst reaction, latest shares, advisers) By Sylwia Lasek and Ben Hirschler July 21 (Reuters) - Galenica has agreed to buy Relyp

UPDATE 1-Galenica to buy biotech firm Relypsa for $1.5 bln before break-up

(Adds details on deal, more on drug and competitive landscape) By Sylwia Lasek July 21 (Reuters) - Galenica has agreed to buy U.S. biotech firm Relypsa for $1.53 billion in cash to strengthen its Vifor Pharma unit ahead of splitting up the Swiss healthcare group. Galenica, which

Your inhaler's watching you: drugmakers race for smart devices

* Digitally connected devices aim to track medicine use * GSK, AstraZeneca, Novartis all working on smart inhalers * Innovation drive comes as sector faces growing competition By Ben Hirschler LONDON, July 20 (Reuters) - Makers of inhalers to treat asthma and chronic lung

Judge refuses to block generic versions of AstraZeneca's Crestor

By Brendan Pierson July 19 (Reuters) - A U.S. judge on Tuesday refused to issue a temporary restraining order blocking the approval of new generic versions of AstraZeneca's blockbuster cholesterol drug Crestor in the United States. U.S. District Judge Randolph Moss in Washington, D.C.

UPDATE 2-U.S. FDA panel backs Valeant psoriasis drug with risk program

(Adds comments from panelists) By Toni Clarke July 19 (Reuters) - Valeant Pharmaceuticals International Inc's experimental drug to treat the skin disorder psoriasis should be approved as long as certain measures are put in place to mitigate the risk of suicide, an advisory committee t

UPDATE 1-U.S. FDA panel backs Valeant psoriasis drug with risk management

(Adds background on studies, paragraphs 3, 4) July 19 (Reuters) - Valeant Pharmaceuticals International Inc's experimental drug to treat the skin disorder psoriasis should be approved as long as certain measures are put in place to mitigate the risk of suicide, an advisory committee to the

U.S. FDA panel backs Valeant psoriasis drug with risk management

July 19 (Reuters) - Valeant Pharmaceuticals International Inc's experimental drug to treat the skin disorder psoriasis should be approved as long as certain measures are put in place to mitigate the risk of suicide, an advisory committee to the U.S. Food and Drug Administration concluded on Tuesd

AstraZeneca's Qtern Gets European Approval For Type 2 Diabetes

LONDON MARKET OPEN: ARM Leads Rising Market But Tour Operators Down

AstraZeneca celebrates success in latest Tagrisso trial

(ShareCast News) - AstraZeneca announced on Monday that the Phase III AURA3 trial has met its primary endpoint, demonstrating superior progression-free survival (PFS) compared to standard platinum-based doublet chemotherapy. The FTSE 100 pharmaceutical giant said the AURA3 randomised trial assessed

TOP NEWS: AstraZeneca Gets Strong Results From Tagrisso Trial

UPDATE 2-Valeant psoriasis drug's suicide risk hard to assess -FDA Staff

(Adds analyst comment, background) July 15 (Reuters) - Valeant Pharmaceuticals International Inc's experimental drug to treat the skin disorder psoriasis carries a potential risk of suicide that is challenging to assess due to limited data, according to a preliminary review by the U.S. Food

UPDATE 1-Valeant psoriasis drug's suicide risk hard to assess -FDA Staff

(Updates with details from FDA review) July 15 (Reuters) - Valeant Pharmaceuticals International Inc's experimental drug to treat the skin disorder psoriasis carries a potential risk of suicide that is challenging to assess due to limited data, a preliminary review by the U.S. Food and Drug

Valeant psoriasis drug safety challenging to assess -FDA Staff

July 15 (Reuters) - Valeant Pharmaceuticals International Inc's experimental drug to treat the skin disorder psoriasis carries several potential risks that are challenging to assess due to limited controlled data, a preliminary review by the U.S. Food and Drug Administration. The review com

BROKER RATINGS SUMMARY: Goldman Sachs Cuts ASOS To Neutral From Buy